Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 101 results found since Jan 2013.

A systematic review of the drug ‐drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies
AbstractColchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electro...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 17, 2022 Category: Drugs & Pharmacology Authors: Nicholas C. Schwier, Cyrille K. Cornelio, Paul M. Boylan Tags: REVIEW Source Type: research

Drug ‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
AbstractLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coadministered with ATV, the effect of multiple-dose letermovir 480  mg once daily on t...
Source: Clinical Pharmacology in Drug Development - February 14, 2022 Category: Drugs & Pharmacology Authors: Jacqueline B. McCrea, Karsten Menzel, Adedayo Adedoyin, Carolyn R. Cho, Sabrina Fox ‐Bosetti, Sreeraj Macha, Tian Zhao, Fang Liu, Deborah Panebianco, S. Aubrey Stoch, Marian Iwamoto Tags: Original Article Source Type: research

Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
Clin Pharmacol Drug Dev. 2022 Feb 14. doi: 10.1002/cpdd.1071. Online ahead of print.ABSTRACTLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coad...
Source: Clinical Genitourinary Cancer - February 14, 2022 Category: Cancer & Oncology Authors: Jacqueline B McCrea Karsten Menzel Adedayo Adedoyin Carolyn R Cho Sabrina Fox-Bosetti Sreeraj Macha Tian Zhao Fang Liu Deborah Panebianco S Aubrey Stoch Marian Iwamoto Source Type: research

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms
Clin Pharmacol Ther. 2022 Feb 12. doi: 10.1002/cpt.2557. Online ahead of print.ABSTRACTStatins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABC...
Source: Clinical Pharmacology and Therapeutics - February 13, 2022 Category: Drugs & Pharmacology Authors: Rhonda M Cooper-DeHoff Mikko Niemi Laura B Ramsey Jasmine A Luzum E Katriina Tarkiainen Robert J Straka Li Gong Sony Tuteja Russell A Wilke Mia Wadelius Eric A Larson Dan M Roden Teri E Klein Sook Wah Yee Ronald M Krauss Richard M Turner Latha Palaniappan Source Type: research

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
Discussion: If the EMSIACS trial endpoints prove statistically significant, the evolocumab added to moderate-intensity statin therapy will have the potential to effectively lower subjects’ LDL-C levels, especially for the Chinese patients with acute phase ACS. However, if the risk of MACE is not significantly different between the two groups, we may extend follow-up time for secondary outcome when the clinical trial is over.Clinical trial registration: The study is registered to ClinicalTrials.gov (NCT04100434), which retrospectively registered on November 24, 2020.
Source: Frontiers in Physiology - November 23, 2021 Category: Physiology Source Type: research

Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records
Conclusion: We report two genetic variants for statin adverse drug reactions (ADRs) that are associated with statin efficacy. While the ABCB1 variant has been shown to have an association with statin pharmacokinetics, no similar evidence for LILRB5 has been reported. These findings highlight the value of genetic testing to deliver precision therapeutics to statin users.
Source: Frontiers in Genetics - October 1, 2021 Category: Genetics & Stem Cells Source Type: research

Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study
CONCLUSIONS: Compared with atorvastatin and rosuvastatin, pitavastatin might be associated with a lower risk of safety events in Asians.PMID:34497171 | DOI:10.5551/jat.63076
Source: Journal of Atherosclerosis and Thrombosis - September 9, 2021 Category: Cardiology Authors: Jia-Ling Lin Po-Sheng Chen Hui-Wen Lin Liang-Miin Tsai Sheng-Hsiang Lin Yi-Heng Li Source Type: research

Statin-Induced Autoimmune Necrotizing Myopathy
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211028714. doi: 10.1177/21501327211028714.ABSTRACTStatin therapy is a widely prescribed medication class for hypercholesterolemia. In statin-induced autoimmune myopathy, genetically predisposed and at-risk patients can develop antibodies against hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the key enzyme in the production of cholesterol. As a result, an autoimmune reaction causing weakness, myalgia, with possible severe rhabdomyolysis, renal failure, and myonecrosis also can occur. A 73-year-old female presented to clinic with myalgia and fatigue. She was on atorvast...
Source: Primary Care - July 5, 2021 Category: Primary Care Authors: Sahani Jayatilaka Kunal Desai Swarup Rijal Debra Zimmerman Source Type: research

Effect of SLCO1B1 T521C on Statin-related Myotoxicity with Use of Lovastatin and Atorvastatin
Clin Pharmacol Ther. 2021 Jun 11. doi: 10.1002/cpt.2337. Online ahead of print.ABSTRACTThe association between the c.521T>C variant allele in SLCO1B1 (rs4149056) and simvastatin-induced myotoxicity was discovered over a decade ago; however, whether this relationship represents a class effect is still not fully known. The aim of this study was to investigate the relationship between rs4149056 genotype and statin-induced myotoxicity in patients taking atorvastatin and lovastatin. Study participants were from the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. A total of 233 statin-induced myopathy +...
Source: Clinical Pharmacology and Therapeutics - June 11, 2021 Category: Drugs & Pharmacology Authors: Brian Lu Laura Sun Manuel Seraydarian Thomas J Hoffmann Marisa W Medina Carlos Iribarren Ronald M Krauss Neil Risch Akinyemi Oni-Orisan Source Type: research